ClinicalTrials.gg
RecruitingNCT06321302Updated Nov 12, 2026

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

A Phase 2 interventional study of BI 764524 and Sham comparator to BI 764524 in Diabetic Retinopathy, sponsored by Boehringer Ingelheim. Recruiting at 90 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 55 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Planned enrollment
66th of 196
175 · median 72
Started
2024
with 10 others
Phase 2
52 of 267
3 open now
Primary completion
2027-03
later than 22 of 53 live
Registered
231st of 267
by date
Lead sponsor
4 of 267
Boehringer Ingelheim

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 66th largest by planned enrollment of the 196 interventional ones that give a count, is one of 11 that started in 2024, is one of 52 in phase 2, reaches primary completion later than 22 of the 53 other live ones, and was the 231st registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.

The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a suitable treatment plan for BI 764524. Participants are put into 5 groups by chance. Participants in groups 1, 2, and 3 get BI 764524. Over 1 year, they get a different number of injections of the same dose of BI 764524 injected into 1 eye. During some visits, participants may get a sham control, which is done like an eye injection but without a needle, so that participants will not know how many injections of BI 764524 they received. Participants in group 4 only get a sham control. Participants in group 5 (only in the USA) get aflibercept or sham injections during some visits. Aflibercept is a medicine already used to treat diabetic retinopathy.

Participants are in the study for one and a half years. During this time, they visit the study site at least 16 times. During this time, doctors regularly do eye exams and visual tests to assess the severity of participants' eye condition. After 1 year of treatment, researchers look at the number of participants with eye improvements. To do so, they compare eye damage and certain severe eye problems between the groups of participants. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General inclusion criteria

  • Diagnosis of diabetes mellitus (DM) under regular treatment with (HbA1c) (glycated haemoglobin) (HbA1c) \<12%; DM should be under regular investigation by a trained specialist as per local standard of care prior to and during the trial
  • Age ≥18 years at time of signing Form (ICF)

Ocular inclusion criteria: study eye

  • Moderate to severe non-proliferative diabetic retinopathy (NPDR) (Diabetic Retinopathy Severity Scale (DRSS) level 43 to 53) as assessed by Ultra-widefield colour fundus photography (UWF-CFP) images (within the 7-field grid) and confirmed by the central reading centre (CRC) at screening. Patient staged at DRSS level of 43 based on UWF-CFP images can be included only if:

    • They are participating in the standard 7-field CFP sub-study of the trial, and
    • They are staged as DRSS level of 47 to 53 on standard 7-field CFP imaging, as confirmed by the CRC at screening.
  • Ultra-widefield fluorescein angiography (UWF-FA) image gradable for presence of retinal non-perfusion (RNP) as confirmed by the CRC at screening
  • Visual acuity: best corrected visual acuity (BCVA) letter score of ≥49 letters (approximate Snellen equivalent of 20/100 or better) using ETDRS chart at starting distance of 4 meter (m) at screening and reconfirmed at baseline
  • Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging

Main exclusion criteria in study eye:

- Evidence of active retinal neovascularisation (NV) on clinical exam and/or UWF-CFP images within the 7-field grid, confirmed by the CRC grading.

The following are permitted if, based on the assessment of the investigator, do not require acute treatment:

  • Small neovascular lesions within the ETDRS 7-field that are detected only on UWF-FA, but not on clinical exam or UWF-CFP
  • Neovascularisations outside of the ETDRS 7-field on ultra-widefield imaging

    • Evidence of active NV of the iris (small iris tufts are not an exclusion) or in the anterior chamber angle
    • Prior pan-retinal photocoagulation (PRP). Peripheral scatter or targeted laser treatment in up to 1 quadrant outside the ETDRS 7-field area is permitted if it was performed at least 6 months prior to Day 1
    • CI-DME, defined as central subfield thickness (CST) ≥320 micrometer (μm) as measured by Heidelberg Spectralis optical coherence tomography (OCT) and confirmed by central reading centre (CRC) at screening (equivalent measurements from other OCT machines may be accepted); participants with a CST of 320-330 μm can be included if, in the opinion of the investigator, the participant is not expected to require treatment for CI-DME during the duration of the study (e.g. no profound impact on BCVA, stable CST, etc.). CST must be re-confirmed at baseline. A CRC confirmation of the baseline CST is not required.
    • Previous treatment in the study eye for NPDR and/or diabetic macular edema (DME) with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) (including anti-VEGF/Ang2) or short acting drugs (e.g. triamcinolone) within 6 months prior to Day 1 or >4 treatments within the last 18 months (referred to elsewhere as 'previous IVT treatment').
    • Any previous IVT treatment other than anti-VEGF and short-acting steroids. Previous dexamethasone IVT drug delivery system (Ozurdex) or fluocinolone acetonide intravitreal implant (Iluvien) is not allowed
    • Refractive error of more than -8 dioptres of myopia (spherical equivalent) in the study eye. For patients having undergone refractive or cataract surgery in the study eye, either the pre-operative refractive error or the axial length measurement should be used, at the investigator's discretion. Axial length should be less than 26 mm
    • Any concurrent or past ocular condition in the study eye which, in the judgement of the investigator, could:
  • Require medical or surgical intervention during the study period to prevent or treat vision loss (e.g. advanced cataract, history of retinal detachment or macular hole (Stage 3 or 4) in the study eye)
  • Could likely contribute to a significant loss of BCVA during the study period if left untreated (e.g. advanced epiretinal membrane and/or vitreomacular traction, active or history of optic neuritis in either eye)
  • Contraindicate the use of the drug, or may render the patient at high risk for treatment complications (e.g. active infectious or non-infectious conjunctivitis/keratitis in either eye; history of recurrent infectious or inflammatory ocular disease in either eye (e.g. uveitis)
  • May affect interpretation of the study results (e.g. central atrophy of the retinal pigment epithelium or photoreceptors; age-related macular degeneration, hereditary retinal degenerative diseases, myopic macular degeneration, past, current or planned use of medications known to be toxic to the retina, lens or optic nerve (e.g. deferoxamine, chloroquine/hydroxychloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol); history of central serous chorioretinopathy, ischemic optic neuropathy or retinal vascular occlusion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
175 participants (estimated)

Study arms

  • Experimental
    BI 764524

    BI 764524

    Drug: BI 764524

  • Sham comparator
    Sham comparator to BI 764524

    Sham comparator to BI 764524

    Drug: Sham comparator to BI 764524

  • Active comparator
    Aflibercept (Eylea®) - US only

    Aflibercept (Eylea®) - US only

    Drug: Aflibercept (Eylea®) - US only

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of a ≥2-step improvement compared with baseline in Diabetic Retinopathy Severity Scale (DRSS) level in the study eye at Week 52 as assessed by Ultra-widefield colour fundus photography (UWF-CFP) images (within the 7-field grid)

    The DRSS is a scale which can take on the following discrete values: 10, 20, 35, 43, 47, 53, 61, 65, 71, 75, 81, 85. Here 10 means "No retinopathy" and 85 means "Advanced proliferative diabetic retinopathy, with posterior fundus obscured, or centre of macula detached". Thus, a higher score means symptoms get worse.

    Time frame: At baseline and at Week 52

Secondary outcomes

  1. Occurrence of vision threatening complications (VTC)s defined as proliferative diabetic retinopathy (PDR) and/or anterior segment neovascularisation (NV), or development of CI-DME, in the study eye between baseline and Week 52

    Time frame: At baseline and at Week 52

  2. Absolute change from baseline of best corrected visual acuity (BCVA) [early treatment diabetic retinopathy study (ETDRS) letters] in the study eye at Week 52

    The BCVA score is the number of letters read correctly by the patient.

    Time frame: At baseline and at Week 52

  3. Absolute change from baseline of central subfield thickness (CST) [μm], as assessed by spectral domain optical coherence tomography (SD-OCT), in the study eye at Week 52

    μm= micrometer

    Time frame: At baseline and at Week 52

  4. Occurrence of a ≥2-step worsening of Diabetic Retinopathy Severity Scale (DRSS) in the study eye between baseline and Week 52 as assessed by UWF-CFP images (within the 7-field grid)

    The DRSS is a scale which can take on the following discrete values: 10, 20, 35, 43, 47, 53, 61, 65, 71, 75, 81, 85. Here 10 means "No retinopathy" and 85 means "Advanced proliferative diabetic retinopathy, with posterior fundus obscured, or centre of macula detached". Thus, a higher score means symptoms get worse.

    Time frame: At baseline and at Week 52

  5. Occurrence of proliferative diabetic retinopathy (PDR) and/or anterior segment neovascularisation (NV) in the study eye between baseline and Week 52

    Time frame: At baseline and at Week 52

  6. Development of centre-involved diabetic macular edema (CI-DME) in the study eye between baseline and Week 52

    Time frame: At baseline and at Week 52

  7. Occurrence of drug-related adverse events (AEs) between baseline and end of study (EOS)

    Time frame: up to 72 weeks

  8. Occurrence of ocular AEs in the study eye between baseline and EOS

    Time frame: up to 72 weeks

  9. Occurrence of ocular AEs of special interest in the study eye between baseline and EOS

    Time frame: up to 72 weeks

07

Study locations

2 of 90 sites recruiting
  • Associated Retina Consultants, Ltd.
    Phoenix, Arizona 85020, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • California Retina Consultants-Bakersfield-65523
    Bakersfield, California 93309, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retinal Diagnostic Center
    Campbell, California 95008, United States
    Completed

    Not enrolling at this site — choose another above.

  • The Retina Partners
    Encino, California 91436, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Lugene Eye Institute
    Glendale, California 91204, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retina Associates of Southern California
    Huntington Beach, California 92647, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Byers Eye Institute
    Palo Alto, California 94303, United States
    Completed

    Not enrolling at this site — choose another above.

  • California Eye Specialists Medical Group Inc
    Pasadena, California 91107, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retinal Consultants Medical Group
    Sacramento, California 95825, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retinal Consultants Medical Group
    Sacramento, California 95841, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • California Retina Consultants-Santa Maria-65510
    Santa Maria, California 93454, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Bay Area Retina Associates - Walnut Creek
    Walnut Creek, California 94598, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Colorado Retina Associates
    Lakewood, Colorado 80228, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retina Group of New England, PC
    Waterford, Connecticut 06385, United States
    Completed

    Not enrolling at this site — choose another above.

  • Florida Retina Institute
    Jacksonville, Florida 32216, United States
    Recruiting
  • Florida Retina Consultants
    Lakeland, Florida 33805, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • East Florida Eye Institute
    Stuart, Florida 34994, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Center for Retina and Macular Disease
    Winter Haven, Florida 33880, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retina Consultants Of Hawaii
    ‘Aiea, Hawaii 96701, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Maine Eye Center
    Portland, Maine 04101, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Deep Blue Retina Clinical Research PLLC
    Southaven, Mississippi 38671, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • NJRetina
    Teaneck, New Jersey 07666, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Long Island Vitreoretinal Consultants
    Great Neck, New York 11021, United States
    Completed

    Not enrolling at this site — choose another above.

  • Retina Vitreous Surgeons of Central NY, PC
    Liverpool, New York 13088, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • EyeHealth Northwest
    Portland, Oregon 97225, United States
    Completed

    Not enrolling at this site — choose another above.

  • Charleston Neuroscience Institute - Ladson
    Ladson, South Carolina 29456, United States
    Completed

    Not enrolling at this site — choose another above.

  • Tennessee Retina
    Nashville, Tennessee 37203, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Austin Retina Associates
    Austin, Texas 78705, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retina Research Center, PLLC
    Austin, Texas 78705, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Austin Clinical Research, LLC
    Austin, Texas 78750, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retina Consultants of Texas
    Katy, Texas 77494, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Valley Retina Institute, PA
    McAllen, Texas 78503, United States
    Completed

    Not enrolling at this site — choose another above.

  • Austin Retina Associates
    Round Rock, Texas 78681, United States
    Completed

    Not enrolling at this site — choose another above.

  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retina Consultants of Texas
    San Antonio, Texas 78240, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Retina Consultants of Texas - Schertz
    Schertz, Texas 78154, United States
    Completed

    Not enrolling at this site — choose another above.

  • Retina Associates of Utah
    Salt Lake City, Utah 84107, United States
    Recruiting
  • Universitätsklinikum Bonn AöR
    Bonn, 53127, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Diakonie Klinikum Dietrich Bonhoeffer GmbH
    Neubrandenburg, 17036, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Ulm
    Ulm, 89075, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Semmelweis University
    Budapest, 1085, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • Budapest Retina Associations Kft.
    Budapest, 1133, Hungary
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Jahn Ferenc Del-Pest Hospital
    Budapest, 1204, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • University Debrecen Hospital
    Debrecen, 4032, Hungary
    Completed

    Not enrolling at this site — choose another above.

  • Nozologen Kft.
    Pécs, 7621, Hungary
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Zala Megyei Szent Rafael Korhaz
    Zala, 8900, Hungary
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero Universitaria Careggi
    Florence, 50134, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico
    Milan, 20122, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ospedale San Raffaele S.r.l.
    Milan, 20132, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Universitaria "Federico II"
    Naples, 80131, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • IRCCS Fondazione Bietti
    Roma, 00198, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ospedali Riuniti di Ancona
    Torrette Di Ancona, 60123, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Akita University Hospital
    Akita, 010-8543, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Hyogo Prefectural Amagasaki General Medical Center
    Amagasaki-shi, 660-8550, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hayashi Eye Hospital
    Fukuoka, 812-0011, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fukushima Medical University Hospital
    Fukushima, 960-1295, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Tokyo Medical University Hachioji Medical Center
    Hachioji-shi, 193-0998, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kagawa University Hospital
    Kagawa, Kita-gun, 761-0793, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Kagoshima University Hospital
    Kagoshima, 890-8520, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Nara Medical University Hospital
    Kashihara, 634-8522, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Kobe University Hospital
    Kobe, 650-0017, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Shinshu University Hospital
    Matsumoto-shi, 390-8621, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • National Hospital Organization Tokyo Medical Center
    Meguro-ku, 152-8902, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Aichi Medical University Hospital
    Nagakute, 480-1195, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Hyogo College of Medicine Hospital
    Nishinomiya, 663-8501, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Juntendo University Hospital
    Tokyo, 113-8431, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinika Okulistyczna
    Bydgoszcz, 85-631, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Centrum Diagnostyki i Mikrochirurgii Oka-Lens Sp. z o.o.
    Olsztyn, 10-424, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Warsaw Ophthalmology Hospital
    Warsaw, 01-258, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centrum Medyczne Piasta 47 sp. z o.o.
    Wałbrzych, 58-304, Poland
    Completed

    Not enrolling at this site — choose another above.

  • 4. Military Clinical Hospital with Polyclinic SP ZOZ
    Wroclaw, 50-981, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Emanuelli Research & Development Center
    Arecibo, 00612, Puerto Rico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitari de Bellvitge
    Barcelon, 08907, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitari General de Catalunya
    Sant Cugat Del Vallés, 08195, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Colchester Hospital
    Colchester, CO4 5JL, United Kingdom
    Completed

    Not enrolling at this site — choose another above.

  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Moorfields Eye Hospital
    London, EC1V 2PD, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Western Eye Hospital
    London, NW1 5QH, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • King's College Hospital
    London, SE5 9RS, United Kingdom
    Completed

    Not enrolling at this site — choose another above.

  • Central Middlesex Hospital
    London, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'.For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Mar 2027, 33 months after the start.

Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's planned 33 months is close to that.

Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Mar 20, 2024
StartActual
May 15, 2024
Primary completionEst.
Mar 5, 2027
CompletionEst.
Aug 20, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 15, 2026
Sites
89 sites changed recruiting status (56 now active, not recruiting, 31 now completed, …)
Show 89 sites
  • Associated Retina Consultants, Ltd. · Phoenix, United Statesno status→Active, not recruiting
  • California Retina Consultants-Bakersfield-65523 · Bakersfield, United Statesno status→Active, not recruiting
  • Retina-Vitreous Associates Medical Group · Beverly Hills, United Statesno status→Active, not recruiting
  • Retinal Diagnostic Center · Campbell, United Statesno status→Completed
  • The Retina Partners · Encino, United Statesno status→Active, not recruiting
  • Lugene Eye Institute · Glendale, United Statesno status→Active, not recruiting
  • Retina Associates of Southern California · Huntington Beach, United Statesno status→Active, not recruiting
  • Byers Eye Institute · Palo Alto, United Statesno status→Completed
  • California Eye Specialists Medical Group Inc · Pasadena, United Statesno status→Active, not recruiting
  • Retinal Consultants Medical Group · Sacramento, United Statesno status→Active, not recruiting
  • California Retina Consultants-Santa Maria-65510 · Santa Maria, United Statesno status→Active, not recruiting
  • Bay Area Retina Associates - Walnut Creek · Walnut Creek, United Statesno status→Active, not recruiting
  • Colorado Retina Associates · Lakewood, United Statesno status→Active, not recruiting
  • Retina Group of New England, PC · Waterford, United Statesno status→Completed
  • Florida Retina Institute · Jacksonville, United Statesno status→Recruiting
  • Florida Retina Consultants · Lakeland, United Statesno status→Active, not recruiting
  • East Florida Eye Institute · Stuart, United Statesno status→Active, not recruiting
  • Center for Retina and Macular Disease · Winter Haven, United Statesno status→Active, not recruiting
  • Retina Consultants Of Hawaii · ‘Aiea, United Statesno status→Active, not recruiting
  • Maine Eye Center · Portland, United Statesno status→Active, not recruiting
  • Cumberland Valley Retina Consultants · Hagerstown, United Statesno status→Active, not recruiting
  • Deep Blue Retina Clinical Research PLLC · Southaven, United Statesno status→Active, not recruiting
  • NJRetina · Teaneck, United Statesno status→Active, not recruiting
  • Long Island Vitreoretinal Consultants · Great Neck, United Statesno status→Completed
  • Retina Vitreous Surgeons of Central NY, PC · Liverpool, United Statesno status→Active, not recruiting
  • University Hospitals Cleveland Medical Center · Cleveland, United Statesno status→Active, not recruiting
  • EyeHealth Northwest · Portland, United Statesno status→Completed
  • Charleston Neuroscience Institute - Ladson · Ladson, United Statesno status→Completed
  • Tennessee Retina · Nashville, United Statesno status→Active, not recruiting
  • Austin Retina Associates · Austin, United Statesno status→Active, not recruiting
  • …and 59 more on the registry record
across 2 updates, Oct 15, 2026 – Oct 28, 2026
Enrollment
190 (actual)→175 (estimated)
Oct 15, 2026
Contact
Study contact now listed: added c•••@boehringer-ingelheim.com · •••0127. See the current contact
Oct 15, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Retina Associates of Utah · Salt Lake City, United StatesContact added u•••@bitrialsupport.com · •••2368
  • Florida Retina Institute · Jacksonville, United StatesContact added u•••@bitrialsupport.com · •••2368
across 2 updates, Oct 15, 2026 – Oct 28, 2026
Show all 3 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 28, 2026
    2 sites changed recruiting status (1 now recruiting, 1 now completed)
    Show 2 sites
    • Florida Retina Institute · Jacksonville, United StatesActive, not recruiting→Recruiting
    • Charleston Neuroscience Institute - Ladson · Ladson, United StatesActive, not recruiting→Completed
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Florida Retina Institute · Jacksonville, United StatesContact added u•••@bitrialsupport.com · •••2368
  3. Oct 15, 2026
    Active, not recruiting→Recruiting
    90 sites changed recruiting status (59 now active, not recruiting, 30 now completed, …)
    Show 90 sites
    • Associated Retina Consultants, Ltd. · Phoenix, United Statesno status→Active, not recruiting
    • California Retina Consultants-Bakersfield-65523 · Bakersfield, United Statesno status→Active, not recruiting
    • Retina-Vitreous Associates Medical Group · Beverly Hills, United Statesno status→Active, not recruiting
    • Retinal Diagnostic Center · Campbell, United Statesno status→Completed
    • The Retina Partners · Encino, United Statesno status→Active, not recruiting
    • Lugene Eye Institute · Glendale, United Statesno status→Active, not recruiting
    • Retina Associates of Southern California · Huntington Beach, United Statesno status→Active, not recruiting
    • Byers Eye Institute · Palo Alto, United Statesno status→Completed
    • California Eye Specialists Medical Group Inc · Pasadena, United Statesno status→Active, not recruiting
    • Retinal Consultants Medical Group · Sacramento, United Statesno status→Active, not recruiting
    • Retinal Consultants Medical Group · Sacramento, United Statesno status→Active, not recruiting
    • California Retina Consultants-Santa Maria-65510 · Santa Maria, United Statesno status→Active, not recruiting
    • Bay Area Retina Associates - Walnut Creek · Walnut Creek, United Statesno status→Active, not recruiting
    • Colorado Retina Associates · Lakewood, United Statesno status→Active, not recruiting
    • Retina Group of New England, PC · Waterford, United Statesno status→Completed
    • Florida Retina Institute · Jacksonville, United Statesno status→Active, not recruiting
    • Florida Retina Consultants · Lakeland, United Statesno status→Active, not recruiting
    • East Florida Eye Institute · Stuart, United Statesno status→Active, not recruiting
    • Center for Retina and Macular Disease · Winter Haven, United Statesno status→Active, not recruiting
    • Retina Consultants Of Hawaii · ‘Aiea, United Statesno status→Active, not recruiting
    • Maine Eye Center · Portland, United Statesno status→Active, not recruiting
    • Cumberland Valley Retina Consultants · Hagerstown, United Statesno status→Active, not recruiting
    • Deep Blue Retina Clinical Research PLLC · Southaven, United Statesno status→Active, not recruiting
    • NJRetina · Teaneck, United Statesno status→Active, not recruiting
    • Long Island Vitreoretinal Consultants · Great Neck, United Statesno status→Completed
    • Retina Vitreous Surgeons of Central NY, PC · Liverpool, United Statesno status→Active, not recruiting
    • University Hospitals Cleveland Medical Center · Cleveland, United Statesno status→Active, not recruiting
    • EyeHealth Northwest · Portland, United Statesno status→Completed
    • Charleston Neuroscience Institute - Ladson · Ladson, United Statesno status→Active, not recruiting
    • Tennessee Retina · Nashville, United Statesno status→Active, not recruiting
    • …and 60 more on the registry record
    Enrollment 190 (actual)→175 (estimated)
    Contact Study contact now listed: added c•••@boehringer-ingelheim.com · •••0127. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Retina Associates of Utah · Salt Lake City, United StatesContact added u•••@bitrialsupport.com · •••2368
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06321302
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
May 15, 2024
Primary completion
Mar 5, 2027 (estimated)
Completion
Aug 20, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion